TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00561132

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate
Description: 50 mg twice daily orally for a period of 4 weeks
Study: NCT03782519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty diagnosis
Description: Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
Study: NCT03476135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
Study: NCT01423968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide infusion
Description: Lipopolysaccharide 4 nanogram/kg body weight

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT01166841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSVC line clamped
Description: A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
Study: NCT04142034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the iAmHealthy Behavioral Intervention
Description: iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~* usual care at their clinic for all issues, including overweight and obesity;~* a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~* weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~* 11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter only arm
Description: Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Consecutive Recruitment
Description: Recruitment of study participants through identifying potential participants through their medical records

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Recruitment
Description: Recruitment of potential participants through flyers and advertisements
Study: NCT00752700

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resistance training
Description: Conventional resistance training program (CRT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration resistance training
Description: Whole body vibration resistance training (WBV) on the FITVIBE-platform
Study: NCT02146417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal pressure pneumoperitoneum (12 mmHg)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromuscular block
Study: NCT02675907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Study: NCT03360903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate
Study: NCT04002076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted hand combined with occupational therapy
Description: Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional occupational therapy
Description: Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
Study: NCT03291938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxidative Phosphorylation Inhibitor IACS-010759
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study: NCT03260179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3810
Description: Fasting，oral ，4w on or 3w on/1w off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3810
Description: Fasting，oral ，4w on or 3w on/1w off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3810
Description: Fasting，oral ，4w on or 3w on/1w off
Study: NCT00080665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
Study: NCT02714569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202328
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202328
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Administered orally
Study: NCT00334217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: PSS Cogrehab
Study: NCT03008694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: pet/ct is used as radiotherapy simulation
Study: NCT01713959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System treatment
Description: Ulthera System: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System treatment
Description: Ulthera System: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham treatment
Description: Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
Study: NCT02953600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Dose Spirulina Platensis
Description: As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero Spirulina Platensis
Description: the zero pill-taken group is a comparison for two other groups.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Double Dose Spirulina Platensis
Description: As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
Study: NCT03633851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric intraocular MX60T lens
Description: one eye will receive toric MX60T lens

Intervention type: OTHER
Group type: OTHER
Intervention: Standard MX60 plus corneal incisions
Description: the other eye will receive standard MX60 lens with corneal incisions
Study: NCT00663013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
Study: NCT01623479

Intervention type: DRUG
Intervention: bimatoprost 0.03%
Description: Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Study: NCT01682733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overstitch Endoscopic Suturing System
Description: The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
Study: NCT03843086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction
Description: This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction
Description: This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)
Study: NCT02991638

Intervention type: DRUG
Group type: OTHER
Intervention: Ibrutinib
Description: Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
Study: NCT02634385

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Renal Artery Embolization
Description: Patients will be receiving embolization prior to planned partial nephrectomy.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Partial Nephrectomy (Surgical Resection)
Description: Patients will be undergoing planned partial nephrectomy post embolization.
Study: NCT00561132

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium oxide
Description: Validation of similar appearance and weight to the intervention component orally 1 unit (\<50 mg) twice daily for a period of 4 weeks
Study: NCT00775996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorazepate Dipotassium 15mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clorazepate Dipotassium 15mg Tablets
Study: NCT02798250

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop
Description: Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop
Description: Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
Study: NCT04491565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational video
Description: an interactive educational video was viewed by participants in the intervention arm.
Study: NCT04100577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Today Not Tomorrrow Pregnancy and Infant Support Program
Description: The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
Study: NCT03358251

Intervention type: DEVICE
Group type: OTHER
Intervention: Pocket-X Gel
Description: Pocket-X Gel is a biodegradable in-situ gelling product that is inserted into a pre-cleaned periodontal pocket where it quickly turns into a gel that adheres to the periodontal pocket and acts as a filler and physical barrier against bacterial re-colonization at the site of application. Administration of this product typically causes no discomfort. The product naturally degrades after 1-3 weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling and root planing
Description: Scaling and root planing is a conventional gold-standard treatment for periodontitis. As part of this procedure, subgingival plaque and tartar are removed and root surfaces are planed.
Study: NCT00621361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Intravenous
Study: NCT02407392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non targeted quadrantic biopsies
Description: During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
Study: NCT02891837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~* Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~* Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours.
Study: NCT04392401

Intervention type: BIOLOGICAL
Intervention: Collection of blood samples in order to create a biocollection
Description: Blood samples will be collected at admission in intensive care, at Day 3, Day 7, Day 12 and Day 20 during their hospitalization. Clinical data from routine care will be collected. Vital status will be assessed at Day 28 and Day 90.
Study: NCT00709852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol (ProHance)
Description: Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol (ProHance)
Description: Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
Study: NCT01021215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: 1200 mg twice daily given orally (PO) for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: 1200 mg twice daily given orally (PO) for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg twice daily given orally for 6 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01994655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doing exercise
Description: We want to investigate the effects of exercise on climacteric symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doing exercise
Description: Doing exercise at least 6 months including walking, running, yoga etc.
Study: NCT04545684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: The person will have to imagine different scenarios of manual gripping

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: The placebo group will imagine a place without the presence of humans.